z-logo
open-access-imgOpen Access
Sarpogrelate, a specific 5ht2‐receptor antagonist, improves the coronary microcirculation in coronary artery disease
Author(s) -
Satomura Kimio,
Takase Bonpei,
Hamabe Akira,
Ashida Kazuhiro,
Hosaka Haruhiko,
Ohsuzu Fumitaka,
Kurita Akira
Publication year - 2002
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4950250108
Subject(s) - medicine , cardiology , coronary artery disease , microcirculation , fractional flow reserve , hemodynamics , blood flow , coronary circulation , artery , receptor antagonist , antagonist , myocardial infarction , receptor , coronary angiography
Background : Serotonin (5‐hydroxytryptamine: 5‐HT) reduces the coronary blood flow (CBF) as a product of aggregating platelets. Sarpogrelate, a specific 5HT2‐receptor antagonist, has been reported to increase the coronary collateral flow in humans; however, its effect on the microcirculation is still not fully understood. Hypothesis : This study was undertaken to determine whether sarpogrelate might improve the microcirculation in coronary artery disease (CAD). Methods : To investigate the effect of sarpogrelate on the microcirculation in CAD, we measured CBF in 15 patients with CAD but no significant stenosis in the left anterior descending artery (LAD). The patients were randomly allocated to two groups, including those receiving oral administration of 200 mg of sarpogrelate (SPG, 8 patients, age 61 ± 6 years) and those receiving no medication (controls, 7 patients, age 57 ± 8 years). Prior to and 1 h after the administration of sarpogrelate, or in controls at 1‐h intervals, the average peak velocity (APV) at baseline and hyperemia was measured by an intracoronary Doppler guidewire. Systemic blood pressure (SBP) and cardiac output (CO) were also measured. Results : In the patients receiving SPG, the medication significantly increased the baseline (18 ± 9 to 19 ± 10 cm/s, p < 0.05) and maximal APV (55 ± 9 to 64 ± 31 cm/s, p < 0.05). However, no significant changes were observed in SBP and CO after the administration of SPG. In the control group, there were no significant differences in baseline and hyperemic APV. Conclusion : Sarpogrelate increased both baseline and maximal CBF without changing the systemic hemodynamics. These findings thus support that SPG improves the microcirculation by antagonizing the vasoconstrictive products of the aggregating platelets in CAD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here